HIV Vaccine Studies
In the United States, HIV disproportionately infects certain groups and populations; however, HIV can infect anyone. Worldwide there are currently over 40 million people infected with HIV. That number is growing.
Developing a vaccine is our best hope to control HIV/AIDS. The Vanderbilt HIV Vaccine Study needs healthy, uninfected adults (ages 18-55) from all walks of life to help find a vaccine to prevent HIV infection.
There is no risk of HIV infection from the study vaccines. Volunteers must be available locally for approximately 18 months. Volunteers will be compensated.
Call 936-7327 or email email@example.com for more information.
You can help fight the HIV/AIDS epidemic.
In order to develop a vaccine that will work for everyone, we need help from everyone! ALL RACIAL AND ETHNIC GROUPS ARE ENCOURAGED TO CONTACT OUR PROGRAM.
HVTN 307: A phase 1 clinical trial to evaluate the safety and the immunogenicity of ferritin nanoparticles expressing native-like HIV-1 envelope trimers followed by boost with mRNA lipid nanoparticles encoding a native-like HIV-1 envelope trimer in adults without HIV
HVTN 309: A phase 1 clinical trial in adult participants without HIV and in overall good health to evaluate the safety and immunogenicity of CD4BS CH505M5 Pr-NP1 followed by CH505 TF chTrimer boost both adjuvanted with either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum
HVTN 144: A phase 1 clinical trial to evaluate the safety and immunogenicity of an HIV envelope trimer, N332-GT5 gp140, adjuvanted with SMNP in adult participants without HIV